Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triple oral therapy with SGLT-2 inhibitor + lobeglitazone + metformin in type 2 diabetes inadequately controlled on DPP-4 inhibitor + metformin
KCT0005497Phase 4Completed
- Sponsor
- Chong Kun Dang
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of lobeglitazone and metformin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Chong Kun Dang. Primary endpoints: Glycemic control (likely change in HbA1c) and Safety and tolerability. Started Apr 2021; status: completed.
02
Drugs
lobeglitazonemetformin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on KCT0005497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005497.